Alzheimer’s Disease, Down Syndrome and GFAP People with Down syndrome are at higher risk of developing Alzheimer’s disease than the general population. In fact, by the age of 70, more than 95% of people with Down syndrome will develop Alzheimer’s disease, which is the leading cause of death in this population. This strong association is … Read more
Plasma biomarkers Scientists worldwide are immersed in the race for accurate, non-invasive and accessible biomarkers to detect and diagnose Alzheimer’s Disease. To date, major scientific advances allowed the identification of several biomarkers in cerebrospinal fluid or using positron emission tomography (PET). Yet, these methods are either invasive or expensive and not easily accessible to all … Read more
Blood biomarkers for Alzheimer’s disease Recent developments in blood markers have made possible to track the different pathophysiological processes that occur in Alzheimer’s disease through plasma analysis. Our study “Use of plasma biomarkers for AT (N) classification of neurodegenerative dementias” evaluates three of these markers and has recently been published in the Journal of Neurology, … Read more
The Sant Pau Memory Unit publishes a new study in collaboration with the University of California San Francisco. The study examines the role of neurofilament light chain (NfL) and total tau levels in plasma for the diagnosis of frontotemporal dementia and Alzheimer’s disease. The work entitled “Plasma tau and neurofilament light in frontotemporal lobar degeneration … Read more